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Abstract 
Stif Person Syndrome (SPS) is a rare immune-mediated disabling neurological disorder characterised by muscle spasms 
and high GAD antibodies. There are only a few case reports of autologous haematopoietic stem cell transplantation (auto-
HSCT) as a treatment for SPS.
Objective To describe the UK experience of treating refractory SPS with auto-HSCT.
Methods Between 2015 and 2019, 10 patients with SPS were referred to our institution for consideration of auto-HSCT. 
Eight patients were deemed suitable for autograft and four were treated. Of the treated patients, three had classical SPS and 
one had the progressive encephalomyelitis with rigidity and myoclonus variant. All patients were signiicantly disabled and 
had failed conventional immunosuppressive therapy. Patients were mobilised with Cyclophosphamide (Cy) 2 g/m2 + G-CSF 
and conditioned with Cy 200 mg/kg + ATG followed by auto-HSCT.
Results Despite their signiicantly reduced performance status, all patients tolerated the procedure with no unexpected toxici-
ties. Following autograft, all patients improved symptomatically and stopped all forms of immunosuppressive therapies. Two 
patients were able to ambulate independently from being wheelchair dependent. One patient’s walking distance improved 
from 300 meters to 5 miles and one patient’s ambulation improved from being conined to a wheelchair to be able to walk with 
a frame. Two patients became seronegative for anti-GAD antibodies and normalised their neurophysiological abnormalities.
Conclusions Auto-HSCT is an intensive but well tolerated and efective treatment option for patients with SPS refractory to 
conventional immunotherapy. Further work is warranted to optimise patient selection and establish the eicacy, long-term 
safety, and cost-efectiveness of this treatment.
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Introduction
Stif person syndrome (SPS) is a rare autoimmune neuro-
logical disorder characterised by progressive axial muscle 
stifness, central nervous system hyper-excitability, and 
stimulus sensitive painful muscle spasms. Needle elec-
tromyography (EMG) often shows continuous motor unit 
activity at rest [1, 2]. The combination of these features 
represents the classical form of SPS which is associated 
with antibodies against glutamic acid decarboxylase (anti-
GAD) in around 70% of cases [3].
Other variants include focal or segmental SPS (stif 
limb or stif trunk), para-neoplastic SPS and progressive 
encephalomyelitis with rigidity and myoclonus (PERM), 
which in addition to the classic symptoms of SPS, mani-
fests with brainstem signs, hyperekplexia, myoclonus, 
ataxia and dysautonomia. PERM is associated with anti-
glycine receptor antibodies and is reported to be more 
responsive to immunotherapy [4–6]. Stif Person Spectrum 
Disorder has recently been suggested as an overarching 
term to encompass the various clinical presentations of 
this condition.
The direct pathological role of the anti-GAD and anti-
glycine receptors antibodies is uncertain. The immune-
mediated pathogenesis of SPS is evidenced by co-existing 
autoimmune diseases and partial response to treatments 
such as intravenous immunoglobulin (IVIG), plasmapher-
esis and other immunosuppressive therapies including 
rituximab, mycophenolate and azathioprine [4]. Sympto-
matic improvement can be achieved using agents such as 
diazepam, dantrolene, gabapentin or baclofen. Nonethe-
less, SPS remains a signiicantly disabling condition with 
over half of patients requiring long term mobility aids [7].
Autologous Haematopoietic Stem Cell Transplantation 
(auto-HSCT) has been reported as a treatment option in a 
limited number of SPS patients with promising results [8]. 
Here we describe the UK’s experience in using auto-HSCT 
to treat patients with refractory SPS.
Methods
Between 2015 and 2019 ten patients with SPS were 
referred to our institution, one of three national referral 
centres in the UK, for consideration of auto-HSCT from 
diferent UK and European centres. Patients’ clinical char-
acteristics and outcomes are summarised in Table 1. All 
patients were assessed in a joint neurology and haema-
tology transplant clinic. Before considering auto-HSCT 
the following criteria needed to be met: (1) established 
diagnosis of SPS; (2) signiicant disability secondary to 
SPS; (3) failure of at least one form of immunotherapy; 
and (4) absence of signiicant co-morbidities that would 
increase mortality risk associated with auto-HSCT. Fund-
ing requests from the NHS were made for UK patients.
Patients deemed suitable for auto-HSCT underwent 
detailed assessments including MRI of the brain and spine, 
nerve conduction studies, needle EMG to assess spontaneous 
motor unit activity and blink relex study to assess brainstem 
hyperexcitability. Autoimmune screening included antinuclear, 
para-neoplastic, anti-GAD and anti-glycine antibodies as well 
as immunoglobulins and protein electrophoresis. Gluten sensi-
tivity screening was undertaken including anti-gliadin antibod-
ies, anti-TTG antibodies and anti-endomysial antibodies. This 
is because there is an overlap between anti-GAD associated 
disease and gluten sensitivity [9]. Infection screening included 
HIV, Hepatitis B & C, VZV, CMV, EBV, Toxoplasmosis and 
VDRL. Other baseline pre-transplant assessments included 
echocardiogram and pulmonary function tests.
Of the 10 patients referred, one was found to be stable on 
mycophenolate and was declined transplant (patient E), and 
another was declined due to signiicant co-morbidities con-
ferring an unacceptable risk (patient F). Eight patients were 
deemed suitable for auto-HSCT. Two patients did not proceed 
to transplant because funding requests were declined by their 
health authority (patient G and H). Patient H subsequently 
died from a chest infection. Two patients are currently being 
assessed (patient I and J).
Four patients proceeded to auto-HSCT (patient A, B, C and 
D). Patient A, B and C had classical SPS. Patient D had the 
PERM variant of SPS.
In accordance with current auto-HSCT guidelines [10] 
patients received a standard regimen, with stem cell mobi-
lisation consisting of cyclophosphamide 2 g/m2 and G-CSF 
followed by apheresis to achieve a minimum CD34+ stem 
cell dose of 2 × 106/kg. Auto-HSCT conditioning regimen 
was cyclophosphamide 200 mg/kg (total dose, given as 50 mg/
kg over days − 5 to − 2) with rabbit anti-thymocyte globulin 
(ATG, Thymoglobulin) total dose 6.0 mg/kg (given over days 
− 5 to − 2 as 0.5, 1.0, 1.5 and 1.5 mg/kg respectively with 
methylprednisolone cover) after which autologous periph-
eral blood stem cells were infused (on day 0). This is a non-
myeloablative regimen which is similar to the one used by Dr 
Burt in Chicago for the treatment of this condition except that 
rituximab was not included in our regimen [11].
Data related to the duration of hospital stay, engraftment 
periods and complications of those who proceeded to auto-
HSCT are summarised in Table 2. All patients were followed 
every 6-9 months in a joint neurology and haematology clinic.
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Table 1  Summary of patients’ demographics, clinical phenotypes, neurophysiological and serological proiles, treatments tried and outcomes of patients with Stif Person Syndrome (SPS) 
referred for consideration of auto-HSCT
Patient Age/gender SPS phenotype Co-morbidities EMG/blink relex Antibodies Immunotherapy tried Disease dura-
tion before 
HSCT
Neurological outcome 
after HSCT
A 36/F Classical SPS None Continuous motor unit 
activity/blink relex 
hyperexcitability
GAD > 2000 U/ml IVIG 
Plasmapheresis
8 years Two years from HSCT:
Marked clinical improve-
ment (wheelchair to 
independent walking)
No further immunotherapy 
needed
Anti-GAD and EMG 
remain positive
B 48/F Classical SPS Pulmonary sarcoidosis
Type 1 diabetes
Peripheral neuropathy
Continuous motor unit 
activity/blink relex 
hyperexcitability
GAD > 2000 U/ml IVIG
Rituximab
4 years One year from HSCT:
Marked clinical improve-
ment (wheelchair to 
independent walking)
No further immunotherapy 
needed
Anti-GAD and EMG 
became negative
C 37/F Classical SPS Type 1 diabetes Continuous motor unit 
activity/blink relex 
hyperexcitability
GAD > 2000 U/ml IVIG
Rituximab
9 years Nine months from HSCT:
Marked clinical improve-
ment (from walking 300 
meters to 5 miles)
No further immunotherapy 
needed
Anti-GAD and EMG 
remain positive
D 52/M PERM & Gluten ataxia Pulmonary embolism Blink relex hyperexcit-
ability
GAD 372 U/ml
Glycine positive
Anti-gliadin positive
IVIG 
Plasmapheresis
5 years Three years from HSCT:
Partial clinical improve-
ment (wheelchair to 
frame)
No further immunotherapy 
needed
Anti-GAD, anti-glycine 
and anti-gliadin became 
negative
Blink relex normalised
E 44/M Classical SPS Type 1 diabetes
Gluten sensitivity
Continuous motor unit 
activity/blink relex 
hyperexcitability
GAD > 2000 U/ml IVIG
Plasmapheresis
Mycophenolate
7 years Not transplanted as condi-
tion stable on mycophe-
nolate
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Table 1  (continued)
Patient Age/gender SPS phenotype Co-morbidities EMG/blink relex Antibodies Immunotherapy tried Disease dura-
tion before 
HSCT
Neurological outcome 
after HSCT
F 70/F Classical SPS Type 1 diabetes
Hypothyroidism
Coeliac disease
Bronchiectasis with hae-
mophilus colonisation 
and lobectomy.
Continuous motor unit 
activity
GAD > 2000 U/ml IVIG (not tolerated)
Azathioprine
Methotrexate
20 years Not transplanted due to co-
existing lung disease
G 47/M PERM Recurrent thrombosis of 
AV istula.
Continuous motor unit 
activity in paraspinal 
muscles
GAD negative
Glycine negative
IVIG
Plasmapheresis
Azathioprine
Mycophenolate
9 years Not transplanted
Funding declined
H 53/F Classical SPS Type 1 diabetes
Hypothyroidism
Gluten sensitivity
Psoriatic arthropathy
Sacral abscess
Recurrent sebaceous 
cysts
Continuous motor unit 
activity/blink relex 
hyperexcitability
GAD > 2000 U/ml
Anti-TPO 397 U/ml
IVIG 15 years Not transplanted
Funding declined
Later died from pneumo-
nia (autopsy was not 
done)
I 35/F Classical SPS Deep venous thrombosis
Heparin-induced throm-
bocytopenia
Continuous motor unit 
activity
GAD > 2000 U/ml IVIG
Plasmapheresis
2 years Not transplanted
Ongoing assessment
J 48/F Classical SPS  None Continuous motor unit 
activity
GAD > 2000 U/ml IVIG
Mycophenolate
3 years Not transplanted
Ongoing assessment
PERM Progressive Encephalomyelitis, Rigidity and Myoclonus, Auto-HSCT autologous haematopoietic stem cell transplantation, GAD glutamic acid decarboxylase, EMG electromyography, 
IVIG intravenous Immunoglobulin
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Transplanted patients
Patient A
36-year-old female with no past medical history developed 
lower limbs and para-spinal muscle spasms that progressed 
over 3 months. Severe muscle spasms leading to arching 
of her back were triggered by sudden noise or cutaneous 
touch. Her symptoms continued to progress and she became 
wheelchair-bound 6 months later.
MRI of the neuroaxis and CSF examination were normal. 
Anti-GAD antibodies were positive (> 2000 U/ml). She was 
diagnosed with the classical form of SPS. She responded 
partially to plasmapheresis at the referring centre but con-
tinued to require very frequent treatments and was therefore 
started on IVIG.
When she was reviewed at our institution, she was 
severely disabled by her symptoms requiring regular IVIG 
treatments at a dose of 90 g every 12 days. She was taking 
regular diazepam at a dose of 30 mg per day and morphine 
up to 60 mg a day to control pain. On examination, she had 
brisk relexes and severe clonus. She was exquisitely touch-
sensitive which induced severe prolonged painful muscle 
spasms. The muscle spasms were severe enough to compro-
mise her breathing and she required intermittent oxygen. 
EMG showed continuous muscle ibre activity. Blink relex 
study was abnormal with marked ampliication of the R2 
component recorded following test stimulus in keeping with 
brainstem hyperexcitability (Fig. 2A). Given her extreme 
stimulus sensitivity, she underwent EEG/EMG polygraphy 
recording which captured exaggerated startle response to 
auditory stimuli in keeping with brainstem hyperexcitability 
(Fig. 1). The rest of her work-up and immunology screen 
were negative.
She received auto-HSCT 8 years from the onset of her 
symptoms. Transplantation proceeded with no unexpected 
complications apart from routine toxicities (Table 2).
When reviewed 5 months after auto-HSCT, the majority 
of her neurological symptoms had improved signiicantly. 
She was ambulating independently and required no further 
IVIG but continued to take diazepam. She had mild startle 
Table 2  Summary of data relating length of hospital stay, engraftment time and complications of autologous haematopoietic stem cell transplan-
tation (auto-HSCT) in the four patients treated for refractory stif person syndrome
Patient Age/Gender Complications 
during priming and 
harvesting 
Engraftment 
time after auto-
HSCT (neutro-
phils > 0.5 × 109/L 
and plate-
lets > 20 × 109/L)
Length of hos-
pital stay for 
auto-HSCT
Required blood 
products/ transfu-
sions
Complications dur-
ing auto-HSCT
Long term sequelae
A 36/F Headache
E.coli UTI
Pain
Neutrophils:
13 days
Platelets:
12 days
26 days Yes Enterococcus UTI
Pulmonary embo-
lism
Mucositis and 
rectal bleeding
Post-menopausal 
symptoms
Alive with  no 
complications
B 48/F None Neutrophils:
11 days
Platelets:
never dropped 
below 50
18 days No ESBL UTI
Transient exac-
erbation of 
diabetes due to 
steroids
Alive with  no 
complications
C 37/F Gram-negative 
pantoea agglom-
erans from Hick-
man line-treated 
successfully with 
antibiotics
Neutrophils:
14 days
Platelets:
13 days
21 days Yes Febrile neutrope-
nia covered with 
antibiotics
Transiently 
deranged LFTs
Transient CMV 
and EBV virae-
mia
Alive with  no 
complications
D 52/M None Neutrophils:
11 days
Platelets:
10 days
16 days Yes Coagulase-nega-
tive staphylococ-
cus line infection
Transient EBV 
viraemia
URTI (RSV)
Alive with  no 
complications
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responses. Anti-GAD antibodies remained positive at > 2000 
U/ml.
Repeat EMG undertaken a year post-auto-HSCT 
remained abnormal with continuous motor unit activity. 
Blink relex study with short interstimulus intervals was not 
possible as immediately following the irst electrical stimu-
lus protracted contraction of facial muscle tended to emerge. 
Therefore, no meaningful comparison could be made with 
the previous study. Overall, the neurophysiological assess-
ment continued to show features in keeping with SPS despite 
the clinical improvement.
She was reviewed again 2 years following auto-HSCT and 
was noted to have remained of all immunotherapy and was 
able to walk independently. She reported occasional muscle 
spasms afecting her arms and legs and poor exercise toler-
ance. Neurological examination was normal. She declined 
repeat neurophysiological assessment. Her anti-GAD anti-
bodies remained positive.
Patient B
Forty-eight-year-old female with a past medical history of 
type 1 diabetes, diabetic neuropathy and pulmonary sar-
coidosis presented with intermittent muscle spasms afect-
ing all four limbs. The spasms progressed gradually caus-
ing increasing diiculties with her mobility over a period 
of 4 years. At that point, she was mostly wheelchair-bound 
and only able to ambulate indoors with the help of a frame 
(supplementary electronic material). Painful muscle 
spasms were triggered by cutaneous touching. Prior to her 
referral to our institution she had been diagnosed with stif 
person syndrome and was started on IVIG which helped 
her symptoms. However, she was requiring an infusion 
every 2 weeks. Subsequently, two doses of rituximab were 
given which improved her symptoms but did not reduce 
the need for regular IVIG. She was reliant on diazepam 
and baclofen for symptomatic relief.
When reviewed at our institution she was noted to have 
intermittent sustained muscle spasms on examination. She 
also had clinical signs of length-dependent peripheral neu-
ropathy which was conirmed on nerve conduction stud-
ies. EMG displayed continuous motor potential activity 
and blink relex demonstrated brainstem hyper-excitabil-
ity with lack of suppression of R2 component following 
the test stimulus (Fig. 2Bi). Anti-GAD antibodies were 
positive (> 2000 U/ml) and the rest of her immunology 
screen was negative. Infection screening prior to auto-
HSCT identiied hepatitis B core antigen positivity. In the 
absence of any risk factors, this was thought to be caused 
by repeated IVIG infusions. Hepatitis B DNA PCR was 
negative.
Auto-HSCT was undertaken at our institution 4 years into 
her illness and progressed uneventfully (Table 2). Hepatitis 
B DNA PCR was pre-emptively monitored throughout her 
immunosuppression and remained negative.
When reviewed in clinic 6 months after auto-HSCT, her 
muscle spasms were noted to have improved signiicantly. 
She required no further doses of IVIG but continued to use 
Fig. 1  EEG/EMG polygraphy recording of patient A with classical 
stif-person syndrome capturing exaggerated startle response to an 
unanticipated auditory stimulus. Low intensity unanticipated auditory 
stimulus around 50 dB elicited prominent muscle jerks (within 92 ms 
from stimulus presentation) followed by protracted spasms in multi-
ple muscle groups. Obc orbicularis Oculi, Obr orbicularis oris, Mass 
massetter, Stern sternocleidomastoid, Trap trapezius, Delt deltoid, 
UPA upper abdominals, TA tibialis anterior, STAR sensor marking the 
onset of the unanticipated auditory stimulus
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a small dose of Baclofen. She was no longer requiring a 
wheelchair and started walking with the support of a stick. 
She continued to sufer from fatigue.
Repeat EMG showed signiicant improvement with the 
patient being able to completely suppress all motor unit 
potential activity in muscles that were previously afected 
by severe stifness. The blink relex excitability studies also 
improved with a more suppressed R2 component following 
the test stimulus compared to the R2 component from the 
conditioning stimulus (Fig. 2Bii). She was able to walk 10 
meters in 15.2 s with a stick.
Serologically, anti-GAD antibodies reduced from > 2000 
to < 0.5 U/ml.
A year after auto-HSCT her marked improvement contin-
ued. She was no longer reporting any spasms and was able 
to walk independently for long distances (Electronic supple-
mentary material). Her diabetes control also improved and 
she came of all her anti-diabetic treatments. She walked 10 
meters in 9 s without assistance or stopping. A repeat EMG 
at that point showed no evidence of stif person syndrome. 
Anti-GAD antibodies remained negative.
Patient C
Thirty-seven-year-old female with a history of type 1 dia-
betes. She developed progressive painful muscle spasms 
afecting her core musculature and limbs, which were not 
controlled despite high doses of diazepam (30 mg/day) and 
gabapentin (2700 mg/day). Nine years into her symptoms 
she was able to walk unaided for a maximum of 300 meters. 
She struggled with social anxiety due to muscle spasms, 
which progressed to afect her face and jaw.
Prior to her referral for auto-HSCT the patient had 
received ive courses of IVIG, which provided transient 
beneit. She had three infusions of rituximab, which did not 
relieve her symptoms. Azathioprine was not tolerated.
Neurological examination showed marked stifness of her 
abdominal and para-spinal muscles. EMG showed contin-
ued motor activity in the para-spinal muscles. Blink relex 
study showed evidence of brainstem hyperexcitability. Anti-
GAD antibodies were positive (> 2000 U/ml). The rest of 
the immunology, paraneoplastic and infective screens were 
negative. Auto-HSCT was ofered 9 years after symptom 
onset. There were no major complications from auto-HSCT 
apart from routine toxicities (Table 2).
Nine months after transplantation the patient reported 
marked improvement of the severity of her muscle spasms 
and stifness. She reported mild fatigue but she was able 
to walk for up to 5 miles a day. She continued to use diaz-
epam and gabapentin albeit at much lower doses (10 mg of 
Diazepam/day and 500 mg of Gabapentin/day). Blink relex 
study did not show evidence of brainstem hyperexcitability 
Fig. 2  Blink relex excitability studies at the short inter-stimulus 
interval between a conditioning and a test stimulus after 160 ms. Sin-
gle square pulse electrical stimulation of the supraorbital nerve on 
one side is given at 20–25 mA and 0.2 s pulse width. The polysynap-
tic R2 response which is recorded following a test electrical stimulus 
from the contralateral side is typically supressed at such small inter-
stimulus interval in healthy subjects. The least afected by artefact, 
rectiied R2 waveform contralateral to the site of stimulation was used 
for analysis. In both patient A and patient B (classical stif person 
syndrome) the contralateral R2 component that follows the test stimu-
lus is enhanced (area estimates for R2 between cursors S1b/S1e and 
S2b/S2e are shown in the relevant embedded tables). The pre-HSCT 
study of patient A shows clear enhancement of the R2 response that 
follows the test stimulus in comparison to the earlier R2 waveform 
that followed the conditioning stimulus. For patient B, comparison 
between the pre-HSCT (Bi) and post-HSCT (Bii) examination shows 
relative normalisation of blink relex excitability in the latter; the R2 
area following the test stimulus is relatively suppressed in comparison 
to the R2 area of the conditioning stimulus (Bii). This electrophysi-
ological assessment is used as a semiquantitative assessment of brain-
stem excitability
 Journal of Neurology
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however, limited lumbar paraspinals EMG (patient was nee-
dle phobic) showed continued motor potentials. Anti-GAD 
antibodies remained positive after transplantation.
Patient D
52-year-old male with no signiicant past medical history 
presented with progressive asymmetrical muscle stifness 
afecting initially the right leg but subsequently other parts 
of his body. The stifness progressed over 5 years to involve 
all four limbs, which significantly impaired his ability 
to carry out the activities of daily living. Facial muscles 
involvement interfered with speech and swallowing and he 
occasionally bit his tongue.
Examination revealed marked muscle rigidity, brisk 
relexes and clonus. MRI of the spine showed moderate 
spondylosis which did not account for the patient’s symp-
toms. Serological testing for gluten sensitivity revealed 
positive anti-gliadin antibodies and a gluten-free diet was 
adopted. MRI of the brain showed mild atrophy of the cer-
ebellar hemispheres. MRI spectroscopy demonstrated low 
NAA/Creatine ratio of 0.85 from the superior vermis (nor-
mal over 1.00) (Fig. 3). CSF examination was normal.
Nerve conduction studies were normal. EMG did not 
show continuous motor unit activity however, blink relex 
studies showed evidence of hyper-excitability. Anti-GAD 
antibodies were positive at 372 U/ml. Anti-glycine anti-
bodies were positive. Paraneoplastic, anti-NMDA and anti-
VGKC antibodies were negative.
He was diagnosed with the PERM variant of SPS on the 
basis of the clinical features and the serology results. He was 
started on IVIG which resulted in partial clinical improve-
ment. However, he continued to require infusions at a dose 
of 150 g every 3 months. He could not tolerate Diazepam, 
Baclofen, Tizanidine or Dantrolene. He did not tolerate 
mycophenolate which he tried for 2 months. Over the sub-
sequent years, he became wheelchair-bound and dependent 
on IVIG which he continued for a year.
Auto-HSCT was ofered 5 years after symptom onset. 
While he was being considered for auto-HSCT he devel-
oped deep vein thrombosis and a large saddle pulmonary 
embolism thought to be related to poor mobility and regular 
IVIGs. He was started on rivaroxaban. Auto-HSCT pro-
ceeded uneventfully apart from routine toxicities (Table 2).
Four months after auto-HSCT, his mobility improved 
from wheelchair to a frame. His legs remained stif but arms 
improved signiicantly so he was able to feed and wash him-
self. Anti-GAD and anti-glycine antibodies became nega-
tive. Repeat blink relex study post-transplantation showed 
no evidence of hyperexcitability. He was no longer requiring 
regular IVIG. His speech remained dysarthric but his swal-
lowing normalised. He was no longer biting his tongue. He 
stopped all regular medications.
Two years after auto-HSCT he remained of IVIG and had 
good use of his upper limbs but continued to use a walking 
frame. EMG and blink relex studies remained normal and 
anti-GAD was negative. MRI spectroscopy of the cerebel-
lum showed improvement of his NAA/creatine ratio (Fig. 3).
Discussion
We report our experience in using auto-HSCT to treat four 
patients with refractory SPS.
All four patients experienced marked improvement in 
their symptoms and mobility following treatment. In spite 
of clinical improvement, patient A and C (classical SPS) 
continued to have high circulating anti-GAD antibody titre. 
EMG and blink relex excitability assessment remained 
abnormal in patient A but normalised in patient C. On the 
other hand, patient B (classical SPS) and patient D (PERM) 
became seronegative for circulating antibodies and their 
EMG and blink relex studies normalised. Furthermore, 
MRI spectroscopy values in patient D improved following 
treatment.
Signiicantly, with respect to both clinical impact and 
health resource utilisation all our patients stopped regular 
IVIG and other forms of immunotherapy with sustained 
symptomatic and clinical improvement.
The response to auto-HSCT conirms the autoimmune 
basis of SPS. Continued seropositivity for anti-GAD in 
half of our patients is comparable to the previous two case 
reports of using auto-HSCT to treat SPS [8].
The role of anti-GAD in the pathogenesis of SPS remains 
uncertain. GAD is the rate-limiting step in the decarboxyla-
tion of L-glutamate to γ-aminobutyric acid (GABA). Thus, 
anti-GAD antibodies are postulated to lead to decreased 
levels of GABA in the brainstem and spinal cord resulting 
in dis-inhibition and hyper-excitability [12]. However, sev-
eral observations question anti-GAD pathogenicity in SPS. 
These include lack of correlation of antibody titres and dis-
ease severity [13], absence of anti-GAD antibodies in some 
SPS patients [14] and reports of clinical improvement with 
ongoing high circulating antibodies [8].
Interestingly patient B who became anti-GAD negative 
after auto-HSCT also reported improvement of her diabetic 
control. Thus, anti-GAD may support the diagnosis of SPS 
and other autoimmune dysfunction but does not fully explain 
the pathophysiology.
Fig. 3  MRI spectroscopy of 52-year-old male with stif person syno-
nym (PERM - patient D) who underwent autologous haematopoi-
etic stem cell transplantation (auto-HSCT). The MRI demonstrate 
cerebellar involvement showing NAA/creatine ratio of 0.85 from 
the superior vermis (normal above 1.00) before auto-HSCT which 
improved to 0.93 after auto-HSCT
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Glycine receptors are inhibitory receptors found on the 
neuronal cell surface predominantly in the brainstem and 
spinal cord. They exert their efects through chloride cur-
rent resulting in membrane hyperpolarisation and reduction 
in excitation [15]. Antibodies against the alpha-1 subunit of 
glycine receptors are, therefore, associated with hyperexcit-
ability. Null mutations in glycine receptors result in heredi-
tary hyperekplexia characterised by an excessive startle and 
often muscle rigidity [16].
When anti-glycine receptor antibodies are present, they 
are typically associated with the PERM variant of SPS [5]. 
However, anti-glycine receptors antibodies are also found 
in around 15% of patient with classical SPS patients with 
uncertain signiicance [17]. Furthermore, glycine receptor 
antibodies have been reported to occur in other autoimmune 
conditions with heterogeneous phenotypes including ataxia, 
limbic encephalitis and myoclonic epilepsy [16].
The pathogenic roles of B cell and T cell immunity in 
SPS are similarly not well deined. Intrathecal production of 
oligoclonal anti-GAD IgG antibodies is continued by active 
B cells with the help of T cells that are activated by neural 
antigens [18]. Thus, immuno-ablative therapy to eliminate 
the dysfunctional immune response is expected to ofer ben-
eit. Immuno-ablative chemotherapy is followed by the re-
introduction of autologous stem cell graft aiming to restart a 
new self-tolerant immune system. The CSF was not assayed 
for the presence of anti-GAD antibodies in our patients, but 
this should be considered in future studies to assess whether 
this parameter would correlate with treatment response.
At the time of writing of this case series all our trans-
planted patients manifested sustained clinical improvement 
without the need for any form of immunotherapy. Follow-
up post-transplant has ranged from 12 months to 3 years. 
No patient encountered major or unexpected complications. 
Longer-term beneit of auto-HSCT in SPS remains to be 
ascertained.
Autologous HSCT has shown promise as a treatment 
option for a range of treatment-refractory autoimmune neu-
rological conditions such as multiple sclerosis, neuromyelitis 
optica, myasthenia gravis and chronic inlammatory demy-
elinating polyneuropathy [10, 19]. Our experience further 
supports its use for refractory stif-person syndrome. Auto-
HSCT may prove to be a more cost-efective treatment in 
patients requiring regular treatment with expensive modali-
ties, such as IVIG. Further work is warranted to establish 
long-term safety, eicacy and cost-efectiveness of auto-
HSCT in SPS, along with optimising patient selection and 
transplant technique. This calls for collaboration between 
centres that provide this service.
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